DE
62
2
NDAQ
59
4
PGR
68
4
PCG
61
5
MOS
45
3
HES
67
4
FE
64
4
VRSN
53
4
WYNN
37
3
ADSK
43
3
ZBH
65
3
WHR
43
4
SBUX
45
2
CLX
68
2
HAL
50
6
BF.B
51
-2
PBI
53
4
HON
58
3
TDC
34
3
VMC
62
2
DE
62
2
NDAQ
59
4
PGR
68
4
PCG
61
5
MOS
45
3
HES
67
4
FE
64
4
VRSN
53
4
WYNN
37
3
ADSK
43
3
ZBH
65
3
WHR
43
4
SBUX
45
2
CLX
68
2
HAL
50
6
BF.B
51
-2
PBI
53
4
HON
58
3
TDC
34
3
VMC
62
2
Financhill
Back

Apellis Pharmaceuticals 10K Form

Sell
22

APLS
Apellis Pharmaceuticals

Last Price:
$24.66
Seasonality Move:
7.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $781.4M
Cash Flow: $19.3M
Price / Cash Flow: 0
Annual Sales: $1.84
Price / Book: 13.54

Profitability

EPS (TTM): -1.59000
Net Income (TTM): $-197.9M
Gross Margin: $663.6M
Return on Equity: -83.06%
Return on Assets: -22.95%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 7 years for APLS is 84.93%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 64.13% of Gross Profit Margin.
  • The Research & Development expenses have been 41.92% of Revenue.
  • The Net Earning history of APLS is -25.32% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 1.98
Current Ratio: 4.25
Quick Ratio: 3.68

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 1247.98

APLS Technical Analysis vs Fundamental Analysis

Sell
22
Apellis Pharmaceuticals (APLS) is a Sell

Is Apellis Pharmaceuticals a Buy or a Sell?